早期声门型喉癌的生存率和喉保存：激光手术与放射治疗的随机试验比较。
Survival and Larynx Preservation in Early Glottic Cancer: A Randomized Trial Comparing Laser Surgery and Radiation Therapy.
机构信息
Department of Otorhinolaryngology - Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Department of Otorhinolaryngology - Head and Neck Surgery, University of Turku and Turku University Hospital, Turku, Finland.
出版信息
Int J Radiat Oncol Biol Phys. 2022 May 1;113(1):96-100. doi: 10.1016/j.ijrobp.2022.01.010. Epub 2022 Feb 11.
PURPOSE
The prognosis of glottic T1a laryngeal squamous cell carcinoma (LSCC) is excellent with both transoral laser surgery (TLS) and radiation therapy (RT). Our aim was to compare TLS and RT treatment results in a randomized study.
METHODS AND MATERIALS
Of 56 male patients with glottic T1a LSCC, 31 were randomized for TLS and 25 for RT. Survival and larynx preservation data were collected from medical records.
RESULTS
Five-year overall survival (OS) was 87%, disease-specific survival (DSS) was 97%, and recurrence-free survival (RFS) was 81% in patients treated with TLS. Five-year OS was 92%, DSS was 100%, and RFS was 88% in patients treated with RT. The primary treatment method was not associated with OS, RFS, or DSS in a log-rank test. The larynx preservation rate was similar in both groups (TLS, 97%; RT, 92%; P = .575).
CONCLUSIONS
In a prospective randomized setting oncological outcomes of both treatment modalities (TLS or RT) for T1a LSCC were similar.
目的
声门型 T1a 喉鳞状细胞癌（LSCC）经经口激光手术（TLS）和放射治疗（RT）治疗后预后良好。我们的目的是通过随机研究比较 TLS 和 RT 治疗结果。
方法和材料
56 名男性声门型 T1a LSCC 患者中，31 名随机接受 TLS 治疗，25 名接受 RT 治疗。从病历中收集生存和喉保留数据。
结果
接受 TLS 治疗的患者 5 年总生存率（OS）为 87%，疾病特异性生存率（DSS）为 97%，无复发生存率（RFS）为 81%。接受 RT 治疗的患者 5 年 OS 为 92%，DSS 为 100%，RFS 为 88%。对数秩检验显示，主要治疗方法与 OS、RFS 或 DSS 无关。两组的喉保留率相似（TLS，97%；RT，92%；P=0.575）。
结论
在一项前瞻性随机研究中，T1a LSCC 的两种治疗方法（TLS 或 RT）的肿瘤学结果相似。
Zotero 插件